These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 12414868)

  • 1. Vascular reactivity in hypogonadal men is reduced by androgen substitution.
    Zitzmann M; Brune M; Nieschlag E
    J Clin Endocrinol Metab; 2002 Nov; 87(11):5030-7. PubMed ID: 12414868
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prostate volume and growth in testosterone-substituted hypogonadal men are dependent on the CAG repeat polymorphism of the androgen receptor gene: a longitudinal pharmacogenetic study.
    Zitzmann M; Depenbusch M; Gromoll J; Nieschlag E
    J Clin Endocrinol Metab; 2003 May; 88(5):2049-54. PubMed ID: 12727953
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vascular reactivity in congenital hypogonadal men before and after testosterone replacement therapy.
    Bernini G; Versari D; Moretti A; Virdis A; Ghiadoni L; Bardini M; Taurino C; Canale D; Taddei S; Salvetti A
    J Clin Endocrinol Metab; 2006 May; 91(5):1691-7. PubMed ID: 16492703
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Physiological testosterone replacement and arterial endothelial function in men.
    Sader MA; Griffiths KA; Skilton MR; Wishart SM; Handelsman DJ; Celermajer DS
    Clin Endocrinol (Oxf); 2003 Jul; 59(1):62-7. PubMed ID: 12807505
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Testosterone substitution normalizes elevated serum leptin levels in hypogonadal men.
    Jockenhövel F; Blum WF; Vogel E; Englaro P; Müller-Wieland D; Reinwein D; Rascher W; Krone W
    J Clin Endocrinol Metab; 1997 Aug; 82(8):2510-3. PubMed ID: 9253326
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interrelationships among lipoprotein levels, sex hormones, anthropometric parameters, and age in hypogonadal men treated for 1 year with a permeation-enhanced testosterone transdermal system.
    Dobs AS; Bachorik PS; Arver S; Meikle AW; Sanders SW; Caramelli KE; Mazer NA
    J Clin Endocrinol Metab; 2001 Mar; 86(3):1026-33. PubMed ID: 11238481
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact on lipoprotein profile after long-term testosterone replacement in hypogonadal men.
    Berg G; Schreier L; Geloso G; Otero P; Nagelberg A; Levalle O
    Horm Metab Res; 2002 Feb; 34(2):87-92. PubMed ID: 11972293
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Testosterone replacement therapy does not promote priapism in hypogonadal men with sickle cell disease: 12-month safety report.
    Morrison BF; Reid M; Madden W; Burnett AL
    Andrology; 2013 Jul; 1(4):576-82. PubMed ID: 23606509
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of androgen administration on the growth hormone-insulin-like growth factor I axis in men with acquired immunodeficiency syndrome wasting.
    Grinspoon S; Corcoran C; Stanley T; Katznelson L; Klibanski A
    J Clin Endocrinol Metab; 1998 Dec; 83(12):4251-6. PubMed ID: 9851759
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics, bioefficacy, and safety of sublingual testosterone cyclodextrin in hypogonadal men: comparison to testosterone enanthate--a clinical research center study.
    Salehian B; Wang C; Alexander G; Davidson T; McDonald V; Berman N; Dudley RE; Ziel F; Swerdloff RS
    J Clin Endocrinol Metab; 1995 Dec; 80(12):3567-75. PubMed ID: 8530600
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Testosterone substitution of hypogonadal men prevents the age-dependent increases in body mass index, body fat and leptin seen in healthy ageing men: results of a cross-sectional study.
    Rolf C; von Eckardstein S; Koken U; Nieschlag E
    Eur J Endocrinol; 2002 Apr; 146(4):505-11. PubMed ID: 11916618
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sublingual testosterone replacement improves muscle mass and strength, decreases bone resorption, and increases bone formation markers in hypogonadal men--a clinical research center study.
    Wang C; Eyre DR; Clark R; Kleinberg D; Newman C; Iranmanesh A; Veldhuis J; Dudley RE; Berman N; Davidson T; Barstow TJ; Sinow R; Alexander G; Swerdloff RS
    J Clin Endocrinol Metab; 1996 Oct; 81(10):3654-62. PubMed ID: 8855818
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Loss of lean body and muscle mass correlates with androgen levels in hypogonadal men with acquired immunodeficiency syndrome and wasting.
    Grinspoon S; Corcoran C; Lee K; Burrows B; Hubbard J; Katznelson L; Walsh M; Guccione A; Cannan J; Heller H; Basgoz N; Klibanski A
    J Clin Endocrinol Metab; 1996 Nov; 81(11):4051-8. PubMed ID: 8923860
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Endogenous testosterone and brachial artery endothelial function in middle-aged men with symptoms of late-onset hypogonadism.
    Mäkinen JI; Perheentupa A; Irjala K; Pöllänen P; Mäkinen J; Huhtaniemi I; Raitakari OT
    Aging Male; 2011 Dec; 14(4):237-42. PubMed ID: 21831030
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A biodegradable testosterone microcapsule formulation provides uniform eugonadal levels of testosterone for 10-11 weeks in hypogonadal men.
    Bhasin S; Swerdloff RS; Steiner B; Peterson MA; Meridores T; Galmirini M; Pandian MR; Goldberg R; Berman N
    J Clin Endocrinol Metab; 1992 Jan; 74(1):75-83. PubMed ID: 1727832
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of testosterone replacement therapy on arterial stiffness in older hypogonadal men.
    Yaron M; Greenman Y; Rosenfeld JB; Izkhakov E; Limor R; Osher E; Shenkerman G; Tordjman K; Stern N
    Eur J Endocrinol; 2009 May; 160(5):839-46. PubMed ID: 19174534
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intramuscular testosterone undecanoate: pharmacokinetic aspects of a novel testosterone formulation during long-term treatment of men with hypogonadism.
    Schubert M; Minnemann T; Hübler D; Rouskova D; Christoph A; Oettel M; Ernst M; Mellinger U; Krone W; Jockenhövel F
    J Clin Endocrinol Metab; 2004 Nov; 89(11):5429-34. PubMed ID: 15531493
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A pharmacokinetic study of injectable testosterone undecanoate in hypogonadal men.
    Zhang GY; Gu YQ; Wang XH; Cui YG; Bremner WJ
    J Androl; 1998; 19(6):761-8. PubMed ID: 9876028
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Androgen receptor gene CAG repeat length and body mass index modulate the safety of long-term intramuscular testosterone undecanoate therapy in hypogonadal men.
    Zitzmann M; Nieschlag E
    J Clin Endocrinol Metab; 2007 Oct; 92(10):3844-53. PubMed ID: 17635942
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Androgen deficiency and endothelial dysfunction in men with end-stage kidney disease receiving maintenance hemodialysis.
    Karakitsos D; Patrianakos AP; De Groot E; Boletis J; Karabinis A; Kyriazis J; Samonis G; Parthenakis FI; Vardas PE; Daphnis E
    Am J Nephrol; 2006; 26(6):536-43. PubMed ID: 17159341
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.